AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
100 hedge funds and large institutions have $925M invested in Aimmune Therapeutics in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
4% more funds holding
Funds holding: 96 → 100 (+4)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Holders
100
Holding in Top 10
4
Calls
$11.4M
Puts
$1.24M
Top Buyers
| 1 | +$13.4M | |
| 2 | +$7.21M | |
| 3 | +$3.93M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.62M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.83M |
Top Sellers
| 1 | -$7.1M | |
| 2 | -$4.27M | |
| 3 | -$3.78M | |
| 4 |
TG
TLP Group
Evanston,
Illinois
|
-$3.72M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.23M |